NASDAQ:SLN Silence Therapeutics Q3 2026 Earnings Date & Estimates $19.58 +10.91 (+125.63%) As of 09:53 AM Eastern This is a fair market value price provided by Massive. Learn more. Silence Therapeutics is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for November 10, 2026 at 2:00 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeBefore Market OpensConference Call DateNovember 10, 2026Conference Call2:00 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Silence Therapeutics in Q3 2026Silence Therapeutics is expected to post earnings of -$0.1129 per share on revenue of $0.12 million. In the same quarter a year earlier Silence Therapeutics reported -$0.45 per share on revenue of $0.16 million. Silence Therapeutics last reported on August 10, 2026, posting -$0.26 per share and missing the -$0.1387 consensus estimate. Silence Therapeutics has beaten the consensus EPS estimate in 2 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.1129Expected Revenue$0.12 millionPrior-Year EPS-$0.45Prior-Year Revenue$0.16 millionExpected Revenue Growth-22.0%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.26 (Missed by -$0.1213)EPS Beat Rate2 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Silence Therapeutics Q3 2026 Earnings FAQ When does Silence Therapeutics report Q3 2026 earnings? Silence Therapeutics (NASDAQ:SLN) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Silence Therapeutics' Q3 2026 earnings call? Silence Therapeutics' Q3 2026 earnings conference call is scheduled for Tuesday, November 10, 2026 at 2:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Silence Therapeutics? Analysts expect Silence Therapeutics to post earnings of -$0.1129 per share for Q3 2026. How much revenue is Silence Therapeutics expected to report? The consensus revenue estimate for Silence Therapeutics is $0.12 million for Q3 2026. Silence Therapeutics Earnings HeadlinesGermany's Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion58 minutes ago | wsj.comSilence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany1 hour ago | marketscreener.comMYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.October 19 at 1:00 AM | Profits Run (Ad)Merck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics, Strengthening Rare Disease Pipeline with Innovative siRNA Asset1 hour ago | markets.ft.comSilence Therapeutics plc (SLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comSilence Therapeutics: Making Some Recent NoiseAugust 19, 2026 | seekingalpha.comSee More Silence Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Silence Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Silence Therapeutics and other key companies, straight to your email. Email Address About Silence TherapeuticsSilence Therapeutics (NASDAQ:SLN) plc is a clinical-stage biotechnology company focused on developing medicines that use RNA interference (RNAi) to selectively reduce the production of disease-causing proteins. The company’s approach is designed to act at the genetic level by targeting specific messenger RNA molecules before they are translated into proteins. Silence’s research is supported by its proprietary mRNAi GOLD platform, which is intended to enable the development and delivery of small interfering RNA (siRNA) medicines. The company’s pipeline has included zerlasiran, formerly known as SLN360, an investigational therapy designed to reduce production of lipoprotein(a), a genetically determined cardiovascular risk factor, as well as programs targeting other diseases involving blood disorders and metabolic or cardiovascular pathways. Founded in the United Kingdom, Silence Therapeutics is headquartered in London and serves international markets through its research, clinical-development and commercial collaborations. The company’s shares trade on the Nasdaq Global Select Market under the symbol SLN. Silence continues to advance its proprietary pipeline and partnerships as it works toward developing RNAi-based treatments for patients with serious diseases.View Silence Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/12 - 10/16Could a Trucking Squeeze Become J.B. Hunt’s Biggest Edge?Meta Claims Frontier-Class AI Status With New Muse Wonder ModelsMicrosoft's New AI Chip Could Change the Economics of AIThese 3 Green Stocks Have a Growth Story That Goes Far Beyond WashingtonWomen Drive the Job Market—These 3 Stocks Are Following ThemBank of America Stock Sell-Off Looks Like a Buying Opportunity Upcoming Earnings America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026)Northrop Grumman (10/20/2026)RTX (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
